Amicus Therapeutics Plunges 24.4% Amid Market Concerns

On April 2, 2025, Amicus Therapeutics experienced a significant drop of 24.4% in pre-market trading, indicating a notable shift in investor sentiment towards the biopharmaceutical company.

Amicus Therapeutics has been under scrutiny due to its recent performance, with analysts setting a consensus target price of $16.75, suggesting a potential upside of 105.67%. This target price reflects the market's expectations for the company's future growth and profitability, despite the recent stock price decline.

The stock's recent decline to a 52-week low of $8.09 has raised concerns among investors about the company's short-term prospects. This price drop could be attributed to various factors, including market volatility, regulatory challenges, or disappointing clinical trial results. However, the consensus target price indicates that analysts remain optimistic about the company's long-term potential.